Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 73,800 shares, a decline of 33.9% from the December 15th total of 111,600 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 119,800 shares, the days-to-cover ratio is currently 0.6 days.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB opened at $1.90 on Wednesday. The company has a market capitalization of $27.28 million, a price-to-earnings ratio of -1.90 and a beta of 0.65. The business has a 50 day moving average of $1.78 and a 200 day moving average of $1.54. Chemomab Therapeutics has a 1-year low of $0.46 and a 1-year high of $2.55.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Oppenheimer reiterated an “outperform” rating and issued a $11.00 target price (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).